SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX surged after clinical data for its obesity candidate VK2735 showed continued weight loss with weekly dosing and strong retention of prior weight loss on less-frequent maintenance injections, alongside encouraging tolerability. Traders largely viewed the results as strengthening the drugs competitive position and prompting analyst upgrades, while buyout and short-squeeze talk remained speculative and some questioned the move amid dilution concerns and competition.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs claimed real-time quantum error-correction decoder running on a standard CPU is drawing attention, with bullish traders viewing it as progress toward scalable fault-tolerant systems. Skeptics counter that the demonstration relies on simulations rather than a comparable quantum machine in hardware and question whether the news warrants the stocks move.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions NVIDIA CUDA-Q Logical integration for quantum error-correction research is drawing attention, with traders viewing the reduced physical-qubit overhead as a technical milestone while others are frustrated that the news has not translated into a sustained share-price move. Speculation about further technical updates at quantum-industry events is adding to the discussion, alongside debate over the stocks volatility and broader market pressure.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys first Alloy Kore design win, selected by Coretura for its software-defined commercial-vehicle platform, is drawing attention as a new QNX growth opportunity and a sizable addition to royalty backlog. Traders are largely bullish on the validation but debate how quickly it will translate into revenue, with many looking to upcoming earnings and guidance for confirmation amid frustration that the share-price response has been muted.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned BLA submission for CAN-2409 in localized prostate cancer, alongside anticipated biomarker data and manufacturing-readiness updates. Many traders are bullish on the Phase 3 results and regulatory progress, while others question whether the filing timeline is achievable and cite the CEOs planned share sale as a concern.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Cantor Fitzgeralds upgrade, based on a more optimistic view of Yartemleas commercial potential, is driving attention. Many traders welcomed the move, while others questioned whether the upgrade alone explains the surge and speculated about additional catalysts.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadus lockup expiration made a large block of previously restricted shares tradable, and traders widely blame the resulting supply overhang for the sharp selloff. The community is split between buying the dip and expecting further selling, with some also concerned about dilution from the companys ATM program.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias patent settlement with Teva, which delays generic voclosporin entry and includes Tevas acknowledgment that key patents are valid and enforceable, is driving attention. Traders view it as reducing Lupkynis competition risk and potentially strengthening Aurinias position in remaining generic lawsuits, though those cases are still ongoing and buyout speculation remains unconfirmed.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp rebound toward a key round-number resistance is driving attention, with traders focusing on whether the move can hold and extend. Optimists see a breakout taking shape, while skeptics warn it may be another short-lived pump that fades at resistance.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyagers proposed convertible senior notes offering is driving the discussion, with traders concerned about potential dilution and repeated fundraising weighing on shareholder confidence. Some see the selloff as a buying opportunity, but frustration with management and the stocks weak performance dominates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences Citius Pharmaceuticals to Participate in September 2026 Investor Conferences PR Newswire CRANFORD, N.J., Sept. 3, 2026 Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright...

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Aug. 14, 2026 $7.1 Million in revenue for the first...

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Aug. 14, 2026 $7.1 million in revenue for the first nine months...

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri PR Newswire CRANFORD, N.J., Aug. 12, 2026 CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology...

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment PR Newswire CRANFORD, N.J., Aug. 5, 2026 New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-universal...

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption PR Newswire CRANFORD, N.J., July 21, 2026 Expanded...

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin...

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR...

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides...

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and...

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

Citius Pharmaceuticals Inc

Neutral Sentiment

Job displacement

Market bubble / overvaluation

Loss of human oversight / control

Killer robots 🤖

As AI spending accelerates across hyperscalers and valuations climb to historic highs, investors and workers alike are increasingly debating the risks the technology poses - from job displacement to fears about losing human oversight over increasingly autonomous systems. What do you think is the biggest threat AI poses? Vote and explain your reasoning in the comments.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.41	--	--	N/A
Q3 '26	-$0.36	-$0.34	5.56%	BEAT
Q2 '26	-$0.28	-$0.95	-238.38%	MISSED
Q1 '26	$0.43	-$0.38	-188.39%	MISSED
Q4 '25	-$0.43	-$0.01	97.67%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

CTXR Earnings

Upcoming Earnings: Q4 '26

Historical Earnings